This treatment can cause severe birth defects, death to an unborn baby or potential serious adverse effects during lactation. This treatment should never be used by women who are pregnant or who could become pregnant or could become pregnant within 24 months after stopping the drug.
Fertility preservation options should be discussed with all patients commencing on this treatment.
Females of reproductive potential are advised to use two reliable methods of contraception whilst on therapy and for at least 24 months following the last dose of therapy.
Male patients should use a condom with spermicide (if available), regardless of vasectomy status, when having sexual intercourse with a woman of childbearing potential during therapy and for 6 months after therapy is discontinued.